Aurobindo Pharma Share Price in Focus; Receives US FDA Warning Letter to Eugia Pharma Unit-I

Aurobindo Pharma Limited reported that Unit-I of Eugia Pharma Specialities Ltd. has received a Warning Letter from the US Food and Drug Administration (US FDA). The company disclosed the matter in a filing dated August 14, 2026, 

Unit-I is a formulation manufacturing facility operated by Eugia Pharma Specialities, a wholly owned subsidiary of Aurobindo Pharma. 

OAI Status Preceded Warning Letter 

The facility had earlier received an Official Action Indicated (OAI) status from the US FDA. Aurobindo Pharma had informed the stock exchanges about the OAI status through its May 24, 2026, communication. 

The August 14, 2026, filing also refers to an earlier company communication dated February 27, 2026. The Warning Letter was issued after the facility was placed under OAI status. 

US Supplies Remain Unaffected 

Aurobindo Pharma noted that the Warning Letter has not affected its existing supplies to the US market. The company did not report any disruption to current supplies in the filing. 

Unit-I of Eugia Pharma Specialities contributes around 2% of Aurobindo Pharma’s overall group revenue, according to the company’s disclosure. 

No Details on FDA Observations 

The filing does not give details of the observations or findings cited by the US FDA in the Warning Letter. It only states that the letter followed the OAI status received by Unit-I. 

Aurobindo Pharma said it continues to work with the US FDA and is taking steps related to compliance at the facility. No timeline for the regulatory process was provided in the disclosure. 

Further Disclosure 

The company said it will inform the stock exchanges about further developments. The filing was signed by B. Adi Reddy, Company Secretary, on behalf of Aurobindo Pharma. 

For now, the company has reported no impact on existing US supplies. Unit-I contributes about 2% of group revenue, while details of the FDA observations have not been disclosed. 

Read More: Bansal Wire Industries Board Approves 1:5 Share Split and Leadership Changes! 

Aurobindo Pharma Share Price Performance  

As of August 14, 2026, 12:06 pm, Aurobindo Pharma share price was trading at ₹1,633.90, a 1.77% decrease from the previous closing price. 

Conclusion  

The US FDA Warning Letter is the latest regulatory update concerning Unit-I of Eugia Pharma Specialities. Aurobindo Pharma said existing US supplies have not been affected. The company said it will inform the stock exchanges about further developments. 

Disclaimer: This blog has been written exclusively for educational purposes. The securities mentioned are only examples and not recommendations. This does not constitute a personal recommendation/investment advice. It does not aim to influence any individual or entity to make investment decisions. Recipients should conduct their own research and assessments to form an independent opinion about investment decisions.   
 
Investments in the securities market are subject to market risks, read all the related documents carefully before investing.